After a post-earnings (I, II) meeting with management, Jefferies isn't too concerned about the...

|By:, SA News Editor

After a post-earnings (I, II) meeting with management, Jefferies isn't too concerned about the recent Medicare/ Medicaid "setback" for Cyberonics' (CYBX +0.5%) VNS Therapy (previous). "The addressable market" could be expanded to include new indications like congestive heart failure analyst Raj Denhoy says, and besides, CYBX "is firing on all cylinders in epilepsy." Ultimately, "strong, sustainable growth" equals a reiterated Buy rating (PT $60).